Oritavancin for Treatment of Osteomyelitis: A Systematic Review and Meta‐Analysis of Observational Studies
Despite previous warnings, we found no evidence of ineffectiveness with ORI for OM. ORI's infrequent dosing schedule may provide convenience over daily parenteral therapy, particularly for difficult-to-treat pathogens like MRSA and VRE. Further research is needed to optimize dosing strategies based on pathogen susceptibility and establish appropriate therapeutic drug monitoring protocols.
Authors
- Taylor D. Steuber (ORCID: https://orcid.org/0000-0002-7656-1504)
- Taylor Morrisette (ORCID: https://orcid.org/0000-0002-1094-043X)
- Alyssa Grimshaw (ORCID: https://orcid.org/0000-0003-3985-0056)
- Andres Felipe Henao-Martinez (ORCID: https://orcid.org/0000-0001-7363-8652)
- Daniel B. Chastain (ORCID: https://orcid.org/0000-0002-4018-0195)
- David Klimpl (ORCID: https://orcid.org/0000-0001-8828-0411)
- Ranjit Sah (ORCID: https://orcid.org/0000-0002-2695-8714)
- Scott W. Mueller (ORCID: https://orcid.org/0000-0003-1238-8199)
- Martin Kršák (ORCID: https://orcid.org/0000-0002-1746-7462)
- Kyle C. Molina (ORCID: https://orcid.org/0000-0002-6764-5984)
Institutions
- University of Colorado Hospital (US)
- Georgia College & State University (US)
- Medical University of South Carolina (US)
- University of Georgia (US)
- St. Elizabeth's Medical Center (US)
- Yale University (US)
- Albany College of Pharmacy and Health Sciences (US)
- University of Missouri–Kansas City (US)
- University of Colorado Denver (US)
Publication Details
- Journal
- Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy
- Published
- 2025-11-01
- DOI
- https://doi.org/10.1002/phar.70072
- Citations
- 1
- Primary Topic
- Orthopedic Infections and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 2.01